Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation

J Heart Lung Transplant. 2003 Feb;22(2):210-3. doi: 10.1016/s1053-2498(02)00564-8.


Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection. Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy. We believe that immunosuppression-induced pneumonitis in a lung allograft is a serious dilemma for lung transplant physicians

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Heart-Lung Transplantation
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Kidney Diseases / drug therapy
  • Lung Diseases, Interstitial / chemically induced*
  • Lung Transplantation*
  • Male
  • Sirolimus / adverse effects*
  • Sirolimus / therapeutic use


  • Immunosuppressive Agents
  • Sirolimus